Open-Label, Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC10004 in Subjects With Severe Plaque Type Psoriasis
Latest Information Update: 27 Apr 2020
Price :
$35 *
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Pharmacodynamics
- Acronyms PSOR001
- Sponsors Amgen; Celgene Corporation
- 24 Oct 2012 New trial record